SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy.
Share this article
Corporate
Score 35
Neutral
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
Mar 12, 2026 07:38 UTC
SCYX
Long term
Related Articles
Score 75
Bullish
JSW Steel Wins Rights to Develop Coking Coal Mine in Mozambique
Mar 14, 06:13
Score 35
Uber ex-CEO Kalanick rebrands latest venture Atoms, expands into mining and transport
Mar 13, 22:04
Score 45
LSEG Plans Up to $3 Billion Bond Sale Next Week
Mar 13, 21:33
Score 85
Nvidia's GTC Event Signals AI Chip Evolution as CPUs Enter the Spotlight
Mar 13, 19:00
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.